Completed

HIGHCARE-AHIGH Altitude CArdiovascular REsearch in the ANDES

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Telmisartan

+ Nifedipine

+ placebo

Drug
Who is being recruted

Cardiovascular Diseases+3

+ Respiration Disorders

+ Respiratory Tract Diseases

From 18 to 65 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 4
Interventional
Study Start: May 2012
See protocol details

Summary

Principal SponsorIstituto Auxologico Italiano
Last updated: April 12, 2013
Sourced from a government-validated database.Claim as a partner

Study start date: May 1, 2012

Actual date on which the first participant was enrolled.

This is a parallel group, prospective, double-blind, placebo controlled randomized trial, comparing the effects of combination of two antihypertensive agents (telmisartan/nifedipine)with placebo in hypertensive subjects exposed to high altitude. The principal objectives are: to assess the response of BP to high altitude exposure in hypertensive subjects residing at sea level To assess the efficacy and safety of combination of telmisartan 80 mg with nifedipine GITS 30 mg in preventing a possible excessive BP increase in hypertensive subjects exposed to high altitude. The following data will be collected during the study at the different steps: Clinical history Symptoms and adverse events questionnaire Conventional BP and heart rate (HR) measurement - seated measurements with a validated oscillometric device will be performed after at least 5 minutes rest on non-dominant arm; two measurements will be performed 1-2 minutes apart and their average will be used in the analyses Vital signs: respiratory rate - will be measured manually over 60 seconds body height and weight, waist circumference blood oxygen saturation (SpO2) Lake Louise Score 24 h ambulatory blood pressure monitoring (ABPM; AND TM2430, AND, Japan) Echocardiography Arterial properties assessment Six minute walking test (6MWT) Cardiopulmonary Exercise Test (CPET) in a subgroup of subjects Polysomnography with a portable device Pulmonary function tests (only at sea level baseline visit) Fluid balance chart Blood and urine analyses: Visit 1: electrolytes, creatinine, estimated glomerular filtration rate (eGFR), glycemia, renin, angiotensin, aldosterone, plasma catecholamines, 24 h urinary sodium excretion, carbonic anhydrase activity and isoenzyme expression (in 50 randomly selected subjects), samples for genetic studies. Visit 2: electrolytes, creatinine, eGFR. Visit 3: complete blood count, electrolytes, creatinine, eGFR, glycemia, insulin, renin, angiotensin, aldosterone, plasma catecholamines, classic urinalysis, microalbuminuria, 24 h urinary sodium excretion, carbonic anhydrase activity and isoenzyme expression (in 50 subjects selected at Visit 1). Visit 4: electrolytes, creatinine, eGFR, glycemia, insulin, renin, angiotensin, aldosterone, plasma catecholamines, 24 h urinary sodium excretion, carbonic anhydrase activity and isoenzyme expression (in 50 subjects selected at Visit 1)

Principal SponsorIstituto Auxologico Italiano
Last updated: April 12, 2013
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

100 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Cardiovascular DiseasesRespiration DisordersRespiratory Tract DiseasesVascular DiseasesAltitude SicknessHypertension

Criteria

Inclusion Criteria: Permanent residence at low (<500 m) altitude Conventional systolic BP (average of two measurements) 140-159 mmHg or conventional diastolic BP 90-99 mmHg in subjects untreated or after 4 weeks of washout Mean daytime systolic BP ≥135 and <150 mmHg and/or mean daytime diastolic BP ≥85 and <95 mmHg in subjects untreated or after 4 weeks of washout Written informed consent to participate in the study Exclusion Criteria: Conventional systolic BP (average of two measurements) ≥150 mmHg and conventional diastolic BP ≥95 mmHg in treated subjects Regular use of two or more antihypertensive drugs (with the exception of subjects on two antihypertensive drugs in low doses) Treated antihypertensive subjects in whom withdrawal of treatment is deemed unethical by the investigator (e.g. because of the existence of compelling indications other than hypertension for continuous use of previously used antihypertensive agent) Contraindications (including a history of adverse reactions) to angiotensin receptor blockers or calcium antagonists History of serious mountain sickness Subjects who over 3 months preceding inclusion in the study spent considerable (> 1 week) amount of time at altitudes above 2500 m. Cardiovascular diseases other than hypertension (coronary heart disease, heart failure, atrial fibrillation, valvular or congenital heart disease, cardiomyopathies, cerebrovascular disease, peripheral artery disease, aortic aneurysm) Suspected or confirmed secondary hypertension Diabetes mellitus Serious respiratory disorders Other conditions deemed relevant by the investigator (including liver disease, renal disease, thyroid disorders) BMI ≥35 kg/m2 Upper arm circumference >32 cm known severe obstructive sleep apnea (apnea-hypopnea index > 30 or use of CPAP) or excessive daytime sleepiness (Epworth Sleepiness Scale > 10) Pregnancy Premenopausal women not using effective contraceptive methods Elevated probability of noncompliance with the study procedures

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination

Group II

Placebo
Two tablets containing placebo daily in the morning

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Universidad Peruana Cayetano Heredia

Lima, PeruOpen Universidad Peruana Cayetano Heredia in Google Maps
CompletedOne Study Center